Bryxta 100mg

Bryxta 100 is a brand name for Bevacizumab, a recombinant humanized monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) in the body. It is used to treat certain types of eye disorders, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Composition:

Each 100 mg injection of Bryxta 100 Bevacizumab 100 mg contains bevacizumab, a humanized monoclonal antibody that targets the vascular endothelial growth factor (VEGF) pathway.

Mechanism of Action: Bevacizumab works by binding to VEGF, which is a protein that promotes the growth of new blood vessels. By inhibiting VEGF, Bevacizumab reduces the formation of new blood vessels and slows down the progression of eye disorders.

Use: Bryxta 100 is used to treat:

1. Wet age-related macular degeneration (wet AMD)
2. Diabetic macular edema (DME)

Dosage: The recommended dosage of Bryxta 100 is:

1. Wet AMD: 0.5 mg every 6 weeks.
2. DME: 0.5 mg every 4 weeks.

Side Effects: Common side effects of Bryxta 100 include:

1. Eye irritation
2. Blurred vision
3. Eye pain
4. Increased intraocular pressure
5. Headache
6. Fatigue
7. Dizziness
8. Nausea
9. Rash

Recommendation: Bryxta 100 should be administered under the guidance of an experienced healthcare provider, usually an ophthalmologist. Patients should be monitored for signs of eye irritation or other side effects.

Important Note:

• Bryxta 100 may cause severe eye problems, including retinal detachment, retinal artery occlusion, and vitreous hemorrhage.
• Patients with a history of severe eye problems or those who are taking anticoagulant medications should be cautious when using Bryxta 100.
• Women of childbearing potential should avoid pregnancy during treatment with Bryxta 100 due to the risk of fetal harm.
• Patients with pre-existing kidney or liver disease should be monitored closely during treatment with Bryxta 100.

It’s important to note that this information is intended to serve as a general overview of Bryxta 100 and its uses, and should not be considered a substitute for medical advice from a qualified healthcare provider or ophthalmologist.